Differin Hlaup 1 mg/g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

differin hlaup 1 mg/g

galderma nordic ab - adapalenum inn - hlaup - 1 mg/g

Suiseng Diff/A Evrópusambandið - íslenska - EMA (European Medicines Agency)

suiseng diff/a

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - svín - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Sunitinib Accord Evrópusambandið - íslenska - EMA (European Medicines Agency)

sunitinib accord

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Æxlishemjandi lyf - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Sutent Evrópusambandið - íslenska - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Æxlishemjandi lyf - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Zinplava Evrópusambandið - íslenska - EMA (European Medicines Agency)

zinplava

merck sharp & dohme b.v. - bezlotoxumab - enterocolitis, pseudomembranous - Ónæmiskerfið sera og mótefni, - zinplava er ætlað til að koma í veg fyrir endurtekna clostridium difficile sýkingu (cdi) hjá fullorðnum sem eru í mikilli hættu á að endurtekna cdi.

Clindamycin EQL Pharma Hart hylki 150 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

clindamycin eql pharma hart hylki 150 mg

eql pharma ab - clindamycinum hýdróklóríð - hart hylki - 150 mg

Clindamycin EQL Pharma Hart hylki 300 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

clindamycin eql pharma hart hylki 300 mg

eql pharma ab - clindamycinum hýdróklóríð - hart hylki - 300 mg

Dalacin Hart hylki 150 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

dalacin hart hylki 150 mg

pfizer aps - clindamycinum hýdróklóríð - hart hylki - 150 mg

Dalacin Hart hylki 300 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

dalacin hart hylki 300 mg

pfizer aps - clindamycinum hýdróklóríð - hart hylki - 300 mg

Lymecycline Actavis Hart hylki 300 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lymecycline actavis hart hylki 300 mg

actavis group ptc ehf. - lymecyclinum inn - hart hylki - 300 mg